[go: up one dir, main page]

WO2000018353A3 - Nouvel inhibiteur de formation de cataracte - Google Patents

Nouvel inhibiteur de formation de cataracte Download PDF

Info

Publication number
WO2000018353A3
WO2000018353A3 PCT/US1999/022354 US9922354W WO0018353A3 WO 2000018353 A3 WO2000018353 A3 WO 2000018353A3 US 9922354 W US9922354 W US 9922354W WO 0018353 A3 WO0018353 A3 WO 0018353A3
Authority
WO
WIPO (PCT)
Prior art keywords
cataract formation
novel inhibitor
mammal
methods
tetracycline derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/022354
Other languages
English (en)
Other versions
WO2000018353A2 (fr
Inventor
Maria Emanuel Ryan
Lorne M Golub
Nungavaram S Ramamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Priority to AU62684/99A priority Critical patent/AU759372B2/en
Priority to JP2000571875A priority patent/JP2002525299A/ja
Priority to KR1020017003876A priority patent/KR20010073190A/ko
Priority to US09/787,866 priority patent/US6914057B1/en
Priority to EP99949910A priority patent/EP1124558A4/fr
Priority to CA002343038A priority patent/CA2343038A1/fr
Priority to NZ510628A priority patent/NZ510628A/en
Publication of WO2000018353A2 publication Critical patent/WO2000018353A2/fr
Publication of WO2000018353A3 publication Critical patent/WO2000018353A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des méthodes de réduction du risque de cataracte chez un mammalien, les méthodes consistant à administrer au mammalien une quantité effective d'un dérivé de tétracycline. De préférence, un dérivé de tétracycline administré selon les méthodes de la présente invention consiste en 6α-désoxy 5-hydroxy-4-dédiméthylaminotétracycline.
PCT/US1999/022354 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte Ceased WO2000018353A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU62684/99A AU759372B2 (en) 1998-09-28 1999-09-28 A novel inhibitor of cataract formation
JP2000571875A JP2002525299A (ja) 1998-09-28 1999-09-28 新規白内障形成抑制剤
KR1020017003876A KR20010073190A (ko) 1998-09-28 1999-09-28 백내장 형성 억제제
US09/787,866 US6914057B1 (en) 1998-09-28 1999-09-28 Inhibitor of cataract formation
EP99949910A EP1124558A4 (fr) 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte
CA002343038A CA2343038A1 (fr) 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte
NZ510628A NZ510628A (en) 1998-09-28 1999-09-28 Use of a tetracycline derivative for reducing the risk of cataract formation in a mammal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10205698P 1998-09-28 1998-09-28
US60/102,056 1998-09-28

Publications (2)

Publication Number Publication Date
WO2000018353A2 WO2000018353A2 (fr) 2000-04-06
WO2000018353A3 true WO2000018353A3 (fr) 2000-07-06

Family

ID=22287890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022354 Ceased WO2000018353A2 (fr) 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte

Country Status (7)

Country Link
EP (1) EP1124558A4 (fr)
JP (1) JP2002525299A (fr)
KR (1) KR20010073190A (fr)
AU (1) AU759372B2 (fr)
CA (1) CA2343038A1 (fr)
NZ (1) NZ510628A (fr)
WO (1) WO2000018353A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1137410T3 (da) * 1998-11-18 2006-12-27 Collagenex Pharm Inc Hidtil ukendte 4-dedimethylaminotetracyclinderivater
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
CA2719162C (fr) * 2001-04-05 2014-12-23 Galderma Pharma S.A. Methodes de traitement de l'acne
JP2004525955A (ja) * 2001-04-05 2004-08-26 コッラジェネックス ファーマシューチカルス インコーポレイテッド テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達
ES2551708T3 (es) * 2002-01-08 2015-11-23 Paratek Pharmaceuticals, Inc. Compuestos de 4-desdimetilamino tetraciclina
ES2391385T3 (es) 2003-04-07 2012-11-23 Supernus Pharmaceuticals, Inc. Formulaciones de doxiciclinas en dosis única diaria
JP5496202B2 (ja) 2008-08-08 2014-05-21 テトラフェース ファーマシューティカルズ，インコーポレイテッド Ｃ７−フルオロ置換テトラサイクリン化合物
EP2427425B1 (fr) 2009-05-08 2017-03-08 Tetraphase Pharmaceuticals, Inc. Composés de tétracycline
US9624166B2 (en) 2009-08-28 2017-04-18 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
AU2013308504B2 (en) 2012-08-31 2016-11-10 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
CN110582486B (zh) 2016-10-19 2024-01-12 四相制药公司 艾若威四环素的结晶形式

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244673A (en) * 1989-09-29 1993-09-14 Institute Of Macromolecular Chemistry Of The Academy Of Sciences Of The Czech Republic Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug
US5474764A (en) * 1993-02-08 1995-12-12 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5814655A (en) * 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0515954A (ja) * 1991-07-10 1993-01-26 Harima Ceramic Co Ltd ポーラス質スライデイングノズルプレート

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244673A (en) * 1989-09-29 1993-09-14 Institute Of Macromolecular Chemistry Of The Academy Of Sciences Of The Czech Republic Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug
US5474764A (en) * 1993-02-08 1995-12-12 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5814655A (en) * 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1124558A4 *

Also Published As

Publication number Publication date
EP1124558A2 (fr) 2001-08-22
JP2002525299A (ja) 2002-08-13
CA2343038A1 (fr) 2000-04-06
WO2000018353A2 (fr) 2000-04-06
AU759372B2 (en) 2003-04-10
KR20010073190A (ko) 2001-07-31
EP1124558A4 (fr) 2004-10-27
AU6268499A (en) 2000-04-17
NZ510628A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
CA2289717A1 (fr) Nouveau traitement de la constipation
AU2122995A (en) Inhibition of cataracts and other disorders
PL335421A1 (en) Method of preventing and retarding occurence of alzheimer diseases as well as preparation therefor
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1999005096A3 (fr) Inhibiteurs d'urokinase
AU6851696A (en) Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
AU3922193A (en) Liposome encapsulated taxol and a method of using the same
AU7578696A (en) Morpholine derivatives and their use as therapeutic agents
AU5729596A (en) Localized use of nitric oxideadducts to prevent internal tis sue damage
EE9900410A (et) Koostised ja meetodid silmasisese rõhu alandamiseks
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
AU1041599A (en) Therapeutic uses of triazolo-pyridazine derivatives
AU5274000A (en) Prevention of regression in refractive keratoplasty
WO2003020202A3 (fr) Methode permettant de reduire l'hypertension et l'insuffisance cardiaque
WO2000018353A3 (fr) Nouvel inhibiteur de formation de cataracte
AU8038998A (en) Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
AU2626895A (en) Production and uses of caffeic acid and derivatives thereof
AU7958100A (en) Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
AU2187197A (en) Transdermally administered acetylcysteine as mucolytic agent
AU2001292818A1 (en) Use of transcription factors for treating inflammation and other diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2343038

Country of ref document: CA

Ref country code: CA

Ref document number: 2343038

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 62684/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 510628

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09787866

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020017003876

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 571875

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999949910

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017003876

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999949910

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 62684/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017003876

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999949910

Country of ref document: EP